Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Eleonora Nicolò, Federica Giugliano, Liliana Ascione, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102395-102395
Closed Access | Times Cited: 124

Showing 26-50 of 124 citing articles:

Therapeutic synthetic and natural materials for immunoengineering
Anna Slezak, Kevin Chang, Samir Hossainy, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 1789-1822
Open Access | Times Cited: 11
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Reprogramming natural killer cells for cancer therapy
Kexin Wang, Linqin Wang, Yiyun Wang, et al.
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2835-2855
Closed Access | Times Cited: 10
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 10
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
Solange Peters, Sherene Loi, Fabrice André, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 607-629
Closed Access | Times Cited: 9
HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
Anna Pous, L. Notario, Cinta Hierro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11403-11403
Open Access | Times Cited: 22
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
Arianna Dri, Grazia Arpino, Giampaolo Bianchini, et al.
Cancer Treatment Reviews (2023) Vol. 123, pp. 102672-102672
Open Access | Times Cited: 21
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
Benjamin Levy, Enriqueta Felip, Martin Reck, et al.
Future Oncology (2023) Vol. 19, Iss. 21, pp. 1461-1472
Open Access | Times Cited: 19
Antibody drug conjugates: hitting the mark in pancreatic cancer?
Nicole L. Wittwer, Michael P. Brown, Vasilios Liapis, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 17
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 7
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Tingrui Zhang, Zongguang Tai, Fengze Miao, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 372-396
Closed Access | Times Cited: 7
Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Veronica Mollica, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104321-104321
Closed Access | Times Cited: 7
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
Yue Wu, Min Zhu, Baihe Sun, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer
Sabrina Nucera, Chiara Conti, Federica Martorana, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1491-1491
Open Access | Times Cited: 6
Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation
Wen‐Jing Qian, Jinshan Yan, Xiaoyu Gang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189187-189187
Closed Access | Times Cited: 6
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Charlotte Bouquerel, Anastasiia Dubrova, Isabella Hofer, et al.
Lab on a Chip (2023) Vol. 23, Iss. 18, pp. 3906-3935
Open Access | Times Cited: 15
Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Ryan A. Heiser, Anthony Cao, Weiping Zeng, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 1, pp. 68-83
Open Access | Times Cited: 15
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
Carmine Valenza, Graziella Rizzo, Maria Ilenia Passalacqua, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 12
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Roberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
British Journal of Cancer (2023)
Open Access | Times Cited: 12
Immunotherapy for HER-2 positive breast cancer
Tingting Yang, Lihua Kang, Dan Li, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Drug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma
Yingying Shao, Ranran Su, Yu Wang, et al.
Acupuncture and Herbal Medicine (2023) Vol. 3, Iss. 3, pp. 189-199
Open Access | Times Cited: 12
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
Mary Anne Fenton, Paolo Tarantino, Stephanie L. Graff
Current Oncology (2023) Vol. 30, Iss. 12, pp. 10211-10223
Open Access | Times Cited: 11
Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities
Geng Jia, Yuqi Jiang, Xiaoyang Li
Pharmaceutical Science Advances (2024) Vol. 2, pp. 100048-100048
Open Access | Times Cited: 4
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
Yijun Dong, Zongliang Zhang, Siyuan Luan, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 10, pp. e009710-e009710
Open Access | Times Cited: 4
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
Yujun Tong, Xiaobing Fan, Huan Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4

Scroll to top